• Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma
  • New Directions in the Frontline Treatment of DLBCL: Implications for Practice
  • Current and Emerging Directions in the Frontline Treatment of Follicular Lymphoma: Implications for Practice
  •  New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice
  • Cardiology-related adverse events of targeted therapies for CLL/SLL and MCL
  • Addressing Disparities in Care for Patients with DLBCL
  • BTK inhibitors in CLL and MCL: Strategies for Managing Adverse Events

What's New

CE Education
Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma
James O. Armitage, MD; John P. Leonard, MD; and Jason Westin, MD, MS, FACP
CE Education
New Directions in the Frontline Treatment of DLBCL: Implications for Practice
James O. Armitage, MD; and Andrew D. Zelenetz, MD, PhD
CE Education
New Directions in the Treatment of Relapsed/Refractory DLBCL: Implications for Practice
James O. Armitage, MD; and Matthew Lunning, DO, FACP
CE Education
Current and Emerging Directions in the Frontline Treatment of Follicular Lymphoma: Implications for Practice
James O. Armitage, MD; and Gilles Salles, MD, PhD
CE Education
Addressing Disparities in Care for Patients with DLBCL
James O. Armitage, MD; and Loretta J. Nastoupil, MD
Newsletters
Cardiology-related adverse events of targeted therapies for CLL/SLL and MCL
Jeremy R. Stone, MD
CE Education
Acute Lymphoblastic Leukemia: Nursing Notes on Asparaginase Hypersensitivity and Silent Inactivation
Katelyn Oranges, MSN, CRNP, CPHON, and Joseph Sciasci, PharmD, BCOP